SynCardia is dedicated to advancing life-saving therapies for patients facing end-stage heart failure. As the manufacturer of the world’s first commercially approved total artificial heart, we partner with physicians, hospitals, and healthcare systems to help provide critically ill patients with additional time while awaiting transplant. Headquartered in Tucson, Arizona, SynCardia is a subsidiary of Picard Medical.
We are pioneering the future of heart replacement—providing the world’s first Total Artificial Heart and developing next-generation systems as an alternative to transplantation.
We are committed to delivering safe, reliable, and high-quality products through disciplined manufacturing, continuous improvement, regulatory compliance, and a patient-first mindset.
Meet Our Leadership Team
SynCardia’s leadership team brings expertise across medical technology, operations, finance, engineering, quality, clinical affairs, and commercial growth—supporting patients and hospitals worldwide.
Company History
SynCardia was founded in Tucson, Arizona by pioneering clinicians and engineers committed to developing a practical total artificial heart therapy for patients with no remaining conventional options. The company was founded by Jack G. Copeland, Richard G. Smith, and Marvin J. Slepian. Built on decades of clinical innovation, SynCardia has helped establish total heart replacement as an important therapy pathway for carefully selected transplant-eligible patients facing imminent risk from biventricular heart failure. Today, SynCardia continues to manufacture and advance total artificial heart technologies while expanding future innovation through next-generation platforms.
Milestones & Innovation
SynCardia’s history reflects continued progress in heart replacement therapy and long-term innovation.
Continuing Innovation
SynCardia and Picard Medical continue development of next-generation fully implantable total artificial heart technologies, including the Emperor platform, designed to advance the future of heart replacement therapy, the Unicorn, meant to reduce driver size and weight while improving patient quality of life, and more.
Currently investigational/under development and not yet approved for commercial sale.
Community Impact
At SynCardia, our mission extends beyond technology. We work alongside hospitals, clinicians, caregivers, and patient advocacy communities to support individuals facing advanced heart failure. Through education, training, and patient support partnerships—including community organizations that help total artificial heart patients and families—SynCardia seeks to improve awareness, access, and outcomes.
We are proud to support the healthcare professionals and transplant centers who make life-saving therapy possible every day.
Build the Future With Us
Join a team committed to engineering, manufacturing, and delivering life-saving medical technologies. SynCardia is advancing mechanical circulatory support for patients with end-stage heart failure through engineering, clinical collaboration, and global program development. Our work is driven by multidisciplinary teams including engineering, clinical affairs, regulatory, manufacturing, quality, and commercial operations. We are committed to supporting innovation that contributes to advanced heart failure care in collaboration with hospitals and healthcare professionals worldwide.
